May. 8 at 8:36 PM
$FEMY Q1 earnings looking pretty solid.
-First profitable quarter -
$846K income vs
$5.9M loss last year
-Revenue up 24.5% to
$425K
-R&D down 55% as they shift from development to commercialization
-Sales/marketing up 45% - exactly what you want to see during rollout
-Inventory building to
$6.1M for commercial scale
The "profit" however includes accounting gains from warrant liabilities, so operations still burning cash...but that's normal during commercialization phase.
Cash runway to Q3 2026 - they'll need financing but this transition to commercial revenue generation makes them an attractive buyout candidate for big pharma looking for proven products in massive markets. In John Canning I trust!!
Bottom line: Fundamentals moving in right direction with patents on
$10B+ addressable markets.
LFG!!
